- ►nih.gov - Free from Publisher B Chua, P Mitchell - British Journal of Ophthalmology, 2004 - bjo.bmj.com Methods: 3654 participants aged 49 years or older participated in the Blue
Mountains Eye Study (BMES I, 1992–4) and 2335 (75·1% of survivors) were
re-examined (BMES II, 1997–9). All participants underwent detailed eye ... Cited by 40 - Related articles - BL Direct - All 8 versions
- ►prsjournal.com J Raftery, A Clegg, J Jones, SC Tan, A Lotery - British Journal of Ophthalmology, 2007 - bjo.bmj.com Two new drugs provide startling benefits in the treatment of age-related macular
degeneration (AMD). The clinical and cost effectiveness of ranibizumab
(Lucentis) was compared to that of bevacizumab (Avastin), which costs up to ... Cited by 38 - Related articles - BL Direct - All 6 versions
OM Durrani, CA Meads, PI Murray - Ophthalmologica, 2004 - content.karger.com Uveitis (intraocular inflammation) is a potentially blinding group of, probably
autoimmune, conditions predominantly occurring in the working age group.
Although the aetiology is unknown in most cases, many patients have an ... Cited by 27 - Related articles - BL Direct - All 7 versions
SM Kymes, MA Kass, DR Anderson, JP Miller … - American journal of ophthalmology, 2006 - Elsevier The incremental cost-effectiveness ratios for treatment of people with ocular
hypertension were $3670 per quality adjusted life-year (QALY) for the Treat
≥5% threshold and $42,430/QALY for the Treat ≥2% threshold. “Treat ... Cited by 16 - Related articles - All 3 versions
- ►uvt.nl [PDF] M Salm, D Belsky, FA Sloan - American journal of ophthalmology, 2006 - Elsevier To estimate impacts of physician-diagnosed eye diseases (age-related macular
degeneration (AMD), cataract, diabetic retinopathy, and glaucoma) on Medicare
payments in the periods 1991 to 1995 and 1996 to 2000. Cited by 17 - Related articles - All 18 versions
N Bansback, S Davis, J Brazier - Eye, 2006 - nature.com A health economic model is used to synthesise the evidence on contrast
sensitivity and treatment rates from the TAP Investigation with health state
utilities and costs. Impairment of visual function is estimated using a ... Cited by 11 - Related articles - BL Direct - All 3 versions
- ►bmj.com [PDF] TH Margrain, B Ryan, JM Wild - British Medical Journal, 2005 - bjo.bmj.com C ataract is the leading cause of blindness in the world, 1 and the leading
cause of low vision in European derived populations. 2 The burden of cataract is
likely to increase as the world's population ages. 2 At present, no ... Cited by 7 - Related articles - BL Direct - All 9 versions
A Peeters, JSAG Schouten, CAB Webers, MH … - Primary open-angle glaucoma and ocular hypertension, 2006 - arno.unimaas.nl 45 4. Cost-effectiveness of early detection and treatment of ocular hypertension
and primary open-angle glaucoma by the ophthalmologist Andrea Peeters 1 Jan SAG
Schouten 1 Carroll AB Webers 1 Martin H. Prins 2, 3 Fred Hendrikse 1 Hans ... Cited by 7 - Related articles - View as HTML - BL Direct - All 4 versions
PP Lee, SP Kelly, RP Mills, CE Traverso, JG … - Journal of Glaucoma, 2007 - journals.lww.com Skip Navigation Links Home > August 2007 - Volume 16 - Issue 5 > Glaucoma in the
United States and Europe: Predicting Costs a... ... Supported by unrestricted
funding from Allergan, Inc, Irvine, CA. ... Reprints: John G. Walt, MBA, ... Cited by 6 - Related articles - BL Direct - All 2 versions
